July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Efficacy and safety of transscleral micropulsed laser in the treatment of glaucoma refractory to treatment
Author Affiliations & Notes
  • Lucia Delgadillo
    Consulta de Especialidad, Fundación Hospital Nuestra Señora de la Luz, Mexico, Mexico
  • Gian Franco Diez
    Glaucoma, Fundación Hospital Nuestra Señora de la Luz, Ciudad de Mexico, Mexico
  • José Francisco Ortega
    Glaucoma, Fundación Hospital Nuestra Señora de la Luz, Ciudad de Mexico, Mexico
  • Footnotes
    Commercial Relationships   Lucia Delgadillo, None; Gian Franco Diez, None; José Francisco Ortega, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 698. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lucia Delgadillo, Gian Franco Diez, José Francisco Ortega; Efficacy and safety of transscleral micropulsed laser in the treatment of glaucoma refractory to treatment. Invest. Ophthalmol. Vis. Sci. 2019;60(9):698.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the use of micropulsed transscleral laser (MP-TSCPC) in patients with glaucoma refractory to treatment.

Methods : A retrospective descriptive study was performed for all patients who underwent treatment with MP-TSCPC in the Glaucoma service at Fundación Hospital Nuestra Señora de la Luz I.A.P. (FHNSL) that where receiving maximal topical and systemic treatment or who persisted with pain due to maintained high intraocular pressure (IOP). Treatment was administered using the P3 probe (Pars Plana Probe) connected to the Iridex Cyclo G6 - Glaucoma Laser System with fixed power of 2000mW, micropulse time on 0.5ms, off 1.1ms with a duty cycle of 31.33%, making a continuous sliding movement from the 9:30 to 2:30 meridians and then the 3:30 to 8:30 meridians with the probe in direct contact with the eye, directing the limbal notch to the sclerocorneal limbus, avoiding passing over the 3 and 9 meridians. IOP was measured previous to treatment and at days 1, 30, 60, 90 and 180 with Goldmann tonometer. Statistical analysis was performed using GraphPad Prism version 5.01 (GraphPad Software Inc.).

Results : A total of 47 eyes were treated in this study. The mean age of patients treated was 50.9 and 51% of them were women. Mean intra ocular pressure (IOP) previous to treatment was 36.15 mmHg and the mean number of hypotensive medications used by patients was 2.74. The mean IOP reduced to 25.43 (p=0.0006), 17.69 (p<0.0001), 22.65(p<0.0001), 30.67(p=0.0073) and 27.22 (p<0.0001) at days 1, 30, 60, 90 and 120 respectively and the mean number of hypotensive medications was 1.98 (p=0.37), 1.54 (p=0.023), 1.18 (p=0.016), 1.22 (p=0.20) and 1.44 (p=0.99) respectively. Three patients presented severe pain. No postoperative hypertensive spike, hypotony, hyphema, fibrinoid uveitis, corneal decompensation, ptisis bulbi, choroidal detachment or cystic macular edema were reported.

Conclusions : The use of MP-TSCPC in this study demonstrates a statistically significant decrease in IOP as well as a reduction in the number of hypotensive medications used by patients. Studies including a greater number of patients and longer follow up time are necessary.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×